Upadacitinib Efficacy for the Treatment of Concomitant Psoriasis and Alopecia Areata

Journal Title: Journal of Dermatology Research - Year 2023, Vol 4, Issue 3

Abstract

Upadacitinib is a selective JAK-1 inhibitor initially approved for the treatment of rheumatoid arthritis and recently psoriatic arthritis (PsA). We present a patient with Atopic Dermatitis (AD), Psoriasis (PsO), PsA and Alopecia Areata (AA) refractory to multiple agents however, successfully treated with upadacitinib. Our patient initially presented with refractory PsO and PsA, leading to treatment with ixekizumab. However, subsequent development of pruritic, erythematous scaly lesions, along with AA, prompted a shift to dupilumab. When distressing PsA and suboptimal outcomes with previous treatments persisted, prior biologics were discontinued and upadacitinib was initiated. Over a three-month period, the patient achieved complete clearance of PsO, significant improvement in AA and resolution of her PsA and AD. This report highlights the therapeutic benefits of upadacitinib in treating inflammatory cutaneous conditions like AA and PsO and further suggests a need for clinical trials to explore its broad therapeutic spectrum.

Authors and Affiliations

Syed Minhaj Rahman1*, Fahad Ahmed2, Adel Haque3,4

Keywords

Related Articles

Rheumatoid Vasculitis: Heterogeneous Clinical Presentation

Vasculitis is defined as a vascular inflammation which may be localized or systemic and mostly idiopathic. Usually it affects several organs of the body such as skin, kidneys and lungs. Vasculitis is one of the biggest...

The Role of Oral Cyclosporine in the Management of Steven Johnson Syndrome and Toxic Epidermal Necrolysis: A Retrospective Multicentric Observational Study

Background: SJS and TEN are severe life threatening muco-cutaneous reactions characterised by extensive epidermal sloughing with mucosal erosions. Objective: The main objective of this study was to observe the effectiv...

Atypical Fibroxanthoma of the Scalp in a Young Woman: A Case Report

Atypical fibroxanthoma, is an uncommon tumor of fibrohistiocytic mesenchymal origin that occurs on the sun-damaged skin of elderly men. The clinical presentation is a solitary cutaneous nodule. The diagnosis is made by...

Immunophenotypes in Atopic Dermatitis

Atopic Dermatitis is a very heterogeneous and complex disease. Recently, the ethnic background has been reported as a determining factor for a better understanding of genetic differences, clinical phenotypes, and immun...

Regenerative Hair Transplantation with Autologous Mesenchymal Cells from The Scalp (Regenerative Hair Transplantation)

Introduction: Androgenetic alopecia is a dynamic and chronic disorder of hair thinning and loss that affects men and women before the age of 70. Objective: To describe the technique for preparing follicular progenitor...

Download PDF file
  • EP ID EP726004
  • DOI https://doi.org/10.46889/JDR.2023.4311
  • Views 49
  • Downloads 0

How To Cite

Syed Minhaj Rahman1*, Fahad Ahmed2, Adel Haque3, 4 (2023). Upadacitinib Efficacy for the Treatment of Concomitant Psoriasis and Alopecia Areata. Journal of Dermatology Research, 4(3), -. https://europub.co.uk/articles/-A-726004